Clinical Development of Novel Drug-Radiotherapy Combinations.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 03 2019
01 03 2019
Historique:
received:
24
08
2018
revised:
16
10
2018
accepted:
26
11
2018
pubmed:
1
12
2018
medline:
9
4
2020
entrez:
1
12
2018
Statut:
ppublish
Résumé
Radiotherapy is a fundamental component of treatment for the majority of patients with cancer. In recent decades, technological advances have enabled patients to receive more targeted doses of radiation to the tumor, with sparing of adjacent normal tissues. There had been hope that the era of precision medicine would enhance the combination of radiotherapy with targeted anticancer drugs; however, this ambition remains to be realized. In view of this lack of progress, the FDA-AACR-ASTRO Clinical Development of Drug-Radiotherapy Combinations Workshop was held in February 2018 to bring together stakeholders and opinion leaders from academia, clinical radiation oncology, industry, patient advocacy groups, and the FDA to discuss challenges to introducing new drug-radiotherapy combinations to the clinic. This
Identifiants
pubmed: 30498095
pii: 1078-0432.CCR-18-2466
doi: 10.1158/1078-0432.CCR-18-2466
pmc: PMC6397668
mid: NIHMS1002664
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1455-1461Subventions
Organisme : Cancer Research UK
ID : 8971
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA166348
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA212007
Pays : United States
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
©2018 American Association for Cancer Research.
Références
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Nat Rev Clin Oncol. 2017 Jun;14(6):365-379
pubmed: 28094262
Lancet Oncol. 2015 Sep;16(10):1153-86
pubmed: 26419354
Nat Rev Clin Oncol. 2016 Oct;13(10):627-42
pubmed: 27245279
Br J Cancer. 2014 Sep 23;111(7):1305-9
pubmed: 25117813
J Natl Cancer Inst. 2013 Jan 2;105(1):11-24
pubmed: 23231975
Lancet Oncol. 2018 May;19(5):e240-e251
pubmed: 29726389
Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):e447-54
pubmed: 22819210
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
Oncologist. 2010;15(4):360-71
pubmed: 20413641
J Clin Oncol. 2007 Sep 10;25(26):4066-74
pubmed: 17827455
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Acta Oncol. 2003;42(5-6):357-65
pubmed: 14596499
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):767-775
pubmed: 29413287
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
J Clin Oncol. 2010 Jun 20;28(18):2996-3001
pubmed: 20479390
J Natl Cancer Inst. 2016 May 19;108(9):
pubmed: 27206636
Clin Oncol (R Coll Radiol). 2014 May;26(5):277-88
pubmed: 24602562
Cancer Res. 2014 Oct 1;74(19):5458-68
pubmed: 25274032
Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):5-7
pubmed: 28587052
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544